


Driving growth & Getting ready for launch



Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “goal”, “intend”, “look forward to”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will”, “would” and similar expressions. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.

Note:

The operating business of Evotec GT commenced on 1 April 2020. In addition, the acquisition of the assets (mainly land and buildings) and the takeover of employees of the Biopark by Sanofi SAS in Toulouse became legally effective on 1 July 2020. The two entities were fully consolidated in the consolidated financial statements from the dates specified above.

Welcome to H1 2021

The Management Team



Werner Lanthaler¹⁾
CEO



Enno Spillner¹⁾
CFO



Craig Johnstone
COO



Cord Dohrmann
CSO


Agenda

Highlights

Financial performance H1 2021


“Building for growth”

Guidance 2021



Strong overall performance and progress in all “lanes”

H1 2021 – Highlights & Lowlights



Highlights

- Business building accelerated, despite COVID-19
- Multiple new & extended integrated drug discovery and development alliances (**EVOiR&D**)
- J.POD® 1 US in Redmond opening August 18th; construction of J.POD® 2 EU to start in Q4 2021 (**EVOaccess**)
- Acquisition of Verona site completed – Now “Campus Levi-Montalcini”
- BMS Oncology protein degradation partnership – significant extension ahead of term
- New protein degradation collaboration in undisclosed therapeutic area also signed with BMS
- PRROTECT, an initiative for pandemic preparedness, launched
- Confidential submission of draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering of American Depositary Shares (after period-end)
- Positive Phase IIb results for Bayer’s eliapixant in patients with refractory chronic cough (RCC) (after period-end) (**EVOroyalty**)

Lowlights

- Slight delays in milestones, but several important milestones imminent

Fully in line with strategy – investments for long-term growth

Financials H1 2021 & FY 2021 Guidance

Strong overall performance

- Group revenues increase by 17% to € 271.3 m (H1 2020: € 231.0 m). Organic growth at record level of 27%
- Adjusted Group EBITDA¹⁾ of € 36.2 m (H1 2020: € 47.3 m) mainly affected by planned **capacity build-up** ahead of imminent production start of J.POD[®] 1 US. Like-for-like growth 13%
- Increase of expenses for unpartnered R&D by 29% to € 27.8 m (H1 2020: € 21.6 m)
- Despite high investments in new J.POD[®] 1 US and other capacity expansions, Net debt leverage ratio remains at even negative level -1.0 x adjusted EBITDA excl. IFRS 16





Confirmation of 2021 outlook & Action Plan 2025 ambitions

- Group revenues € 550 - 570 m (2020: € 500.9 m)
- Adjusted Group EBITDA € 105 -120 m (2020: € 106.6 m)
- Unpartnered R&D € 50 - 60 m (2020: € 46.4 m)
- Action Plan 2025 targets confirmed: Revenues > € 1,000 m, adjusted EBITDA ≥ € 300 m, unpartnered R&D > € 100 m


Our innovation hub addresses the industry's needs

Leadership in efficiency, data, science, multimodality and access

Evotec's integrated platforms

	R&D efficiency platforms¹⁾	Fully integrated AI/ML-driven drug discovery & development platforms	EVO<i>iR&D</i>
	Precision medicine platforms	Industrial scale Omics and iPSC platforms	EVO<i>panOmics</i> & EVO<i>panHunter</i>
	Just – Evotec Biologics¹⁾	AI/ML powered disruptive biologics discovery and manufacturing platforms	EVO<i>access</i>
	Multimodality drug design	Small molecules, biologics, iPSC-based cell therapy, emerging gene therapy toolbox	EVO<i>cells</i> & EVO<i>genes</i>

Core collaboration routes



¹⁾ Also partly accessible as stand alone “Fee-for-service” or FTE rates-based offerings


²⁾ “Fee-for-service” also encompasses FTE rates-based collaborations

Stand-alone & integrated offerings see strong demand

Examples of capabilities & expertise overview

Industry needs

Capabilities & expertise (illustrative)



R&D efficiency platforms¹⁾



Target ID & validation



Hit identification




Sample management



DMPK & ADME-Tox



Research Informatics



Bio Reagents




In vitro biology



In vivo Pharmacology



Biomarker discovery



Integrated CMC



Lead optimisation



INDiGO



Precision medicine platforms



EVOpanOmics



EVOpanHunter



iPSC platform



ScreenSeq™



ScreenPep™



J.HAL™
AI DESIGNED MAB LIBRARY



Just – Evotec Biologics¹⁾



J.DISCOVERY™
MOLECULE DISCOVERY



J.HAL™
AI DESIGNED MAB LIBRARY



J.MD™
MOLECULE DESIGN



JP3®
PROCESS & PRODUCT DESIGN



J.POD®
MANUFACTURING DESIGN



Multimodality drug design




EVOcells




EVOgenes



Antibodies & Bifunctionals



Small molecules



Antisense



Protein degradation



Exosomes



RNA


Agenda

Highlights

Financial performance H1 2021

“Building for growth”

Guidance 2021



Strong growth & investments into capacity, R&D, and SG&A

Condensed income statement H1 2021 – Evotec SE and subsidiaries

in € m¹⁾

	H1 2021	H1 2020	Change
Revenues from contracts with customers	271.3	231.0	17%
<i>Gross margin</i>	20.8%	23.0%	–
• R&D expenses	(35.4)	(29.8)	19%
• SG&A expenses	(46.4)	(36.5)	27%
• Impairment of intangible assets and goodwill	(0.7)	–	-
• Other op. income (expenses), net	34.5	32.2	7%
Operating result	8.3	18.9	(56)%
Adjusted Group EBITDA²⁾	36.2	47.3	(23)%
Net income	112.7	7.3	>>>100%


- Revenue growth 17% (27%, adjusted for portfolio³⁾ & fx effects)
- R&D expenses up 19% as planned
- SG&A up 27% as planned due to upscaling and depreciation, plus final ramp-up J.POD[®] 1 US ahead of opening
- Adj. EBITDA like-for-like growth 13% despite higher R&D and SG&A
- Net income benefits from fair value adjustment of **EVOequity** investment Exscientia

Gross margin affected by ongoing capacity build-up – as planned

Revenues & Gross margin overview – Evotec SE and subsidiaries


Revenues from contracts with customers (in € m)

- Base revenues
- Milestones, upfronts and licences



Gross margin (in %)

- Total Margin
- Margin excl. milestones, upfronts and licences and amortisation



- Base revenues up 17% or € 38.1 m to € 261.3 m. Adjusted for anticipated end of Sanofi subsidy and unfavourable fx effects growth would have reached 22%
- Just – Evotec Biologics added revenues of € 23.0 m, increase of 44%
- Despite higher year-on-year milestone revenues of € 4.1 m (H1 2020: € 2.2 m), some milestone payments still delayed due to COVID-19, but imminent
- Gross margin decreased mainly due to capacity build-up ahead of launch of J.POD® 1 US in Q3 and fx

Strong performance across all business lines

Segment information H1 2021 – Evotec SE and subsidiaries

in € m¹⁾


	EVT Execute	EVT Innovate	Inter- segment elimination	Evotec Group
Revenues	279.5	57.3	(65.5)	271.3
<i>Gross margin</i>	19.0%	16.3%	–	20.8%
• R&D expenses	(1.0)	(40.5)	6.0	(35.4)
• SG&A expenses	(37.2)	(9.2)	–	(46.4)
• Impairment of intangible assets and goodwill	–	(0.7)	–	(0.7)
• Other op. income (expenses), net	11.4	23.2	–	34.5
Operating result	26.2	(17.9)	–	8.3
Adjusted EBITDA²⁾	51.9	(15.7)	–	36.2

- Both segments show very strong performance versus Q1
- EVT Execute: 18% growth including inter-segment revenues implies accelerated demand for integrated offering **EVOiR&D**; 15% growth of external revenues driven by strong base business demand
- EVT Innovate: 27% growth driven by precision medicine platforms
- Adjusted Group EBITDA influenced by end of Sanofi subsidy, unfavourable fx effects, increased R&D investments and planned capacity expansion, reflected by growing SG&A

Growth acceleration continues in second quarter

Revenue bridge H1 2020 – H1 2021 – Evotec SE and subsidiaries


in € m



- 17% growth of Group revenues
- fx effect: € (11.5) m (-5%)
- Organic growth of € 60.4 m translates in record growth rate of 27%, driven by base business and in particular strong demand for **EVOiR&D** offering
- Organic growth reached 28% in Q2 after 26% in Q1


Well-balanced global customer mix further improving

Selected KPIs H1 2021



Double-digit organic EBITDA growth year-on-year

EBITDA bridge H1 2020 – H1 2021 – Evotec SE and subsidiaries



- Pure organic growth of adjusted EBITDA in H1 reached 13%
- fx effect of € 7.4 m amounts to -19%
- Decrease of 23% mainly due to delay of milestones as well as planned investments at all functional levels securing growth and capacity

Capacity build-up temporarily affects margin

Condensed income statement Q2 2021 – Evotec SE and subsidiaries

in € m¹⁾

	Q2 2021	Q2 2020
Revenues from contracts with customers	138.2	111.6
<i>Gross margin</i>	18.5%	17.7%
• R&D expenses	(17.0)	(14.7)
• SG&A expenses	(25.2)	(19.3)
• Impairment of intangible assets	(0.7)	–
• Impairment of goodwill	–	–
• Other op. income (expenses), net	18.8	17.0
Operating result	1.5	2.8
Adjusted Group EBITDA²⁾	15.1	17.3
Net income	60.0	(9.8)

- Base revenues accelerated in Q2 versus Q1 2021 across all business lines while fx headwinds
- R&D investments higher - as planned
- SG&A reflects further dynamic growth and strategic projects
- As a result EBITDA slightly below previous year level
- **EVOequity**: Net Income benefits from 2nd fair value adjustment in 2021 of Exscientia investment

Strong balance sheet supporting accelerated growth

Balance sheet and liquidity – 31 Dec. 2020 vs. 30 June 2021¹⁾ – Evotec SE and subsidiaries

Balance sheet total
in € m

1,462.9 **1,621.1**

Equity Ratio
in %

49.4 **52.6**

Net Debt ratio (excl. IFRS 16)
x adjusted EBITDA²⁾

(1.5) **(1.0)**

Liquidity position
in € m

481.9 **449.3**

- Total assets, liabilities and equity increased by around 11%
- Equity ratio again increased by 3.2 percentage points
- With cash spend in first quarter, net debt leverage ratio remains very comfortable at -1.0 x adjusted EBITDA excl. IFRS 16
- While strong operating cash flow, liquidity decreased € 33 m from investments for J.POD[®] 1 US, capex for growth and continued **EVOequity** engagements


Agenda

Highlights

Financial performance H1 2021


“Building for growth”

Guidance 2021



Record demand – Capacity expansion around the globe

Expansion of footprint at all sites



France – “Campus Curie”

J.POD® 2 EU initiated

Italy – Verona

Acquisition of Verona site from GlaxoSmithKline SpA – Now “Campus Levi-Montalcini”

Germany – Hamburg, Goettingen – “Manfred Eigen Campus”, Munich, Cologne

New building initiated for “The lighthouse of iPSC” in Hamburg; expansion in Munich and Goettingen

UK – Abingdon – “Dorothy Crowfoot Hodgkin Campus”, Manchester

Dorothy Crowfoot Hodgkin Campus and Manchester expansion

USA – Branford, Princeton, Redmond, Seattle, Watertown

- All sites ready for expansion
- J.POD® 1 US operational start in Q4 2021

Austria – Orth

Footprint expansion under evaluation

Campus Levi-Montalcini creates long-term growth opportunities

“Campus Levi-Montalcini” – Acquisition of the Verona site from GlaxoSmithKline SpA



Rita Levi-Montalcini



Ownership improves flexibility

- Acquisition from GSK strengthens fully integrated R&D solutions for partners
- 75,000 m² of state-of-the-art scientific and tertiary facilities plus 38,000 m² plot
- Currently ~ 750 employees in Verona with space to further grow following Action Plan 2025
- “Campus Levi-Montalcini” in commemoration of Italian Nobel laureate Rita-Levi Montalcini

J.POD[®] 1 in US - Grand opening on 18th of August

State-of-the-art manufacturing facility for biologics



- 12,077 m² development and commercial production site
- Certificate of Occupancy in May (employees on site)
- Cost effective and flexible. Intensified production processes are run inside autonomous cleanrooms that can be reconfigured; qualification activities underway
- Production from a few kilograms to metric tons in the same facility
- Initially operational in Q4 2021

New manufacturing options to avoid biologics shortage in EU

Campus Curie home for new J.POD® showcases next-generation options



- Europe is second-largest market for biologics; local capacities to secure supply urgently needed
- J.POD® 2 EU creates operational efficiency and capacity for biological treatments in EU
- Strong support from French government, Occitanie region, Bpifrance, Haute-Garonne prefecture as well as Toulouse Métropole
- Two hectares of land¹⁾ at Campus Curie already identified and design plan started
- Opportunity to build global J.POD® network

EVOTEC ACCELERATES ACCESS TO BIOLOGIC THERAPEUTICS WITH INITIATION OF MANUFACTURING FACILITY IN TOULOUSE

- ▶ J.POD® 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19
- ▶ EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE
- ▶ CONSTRUCTION OF THE J.POD® 2 EU FACILITY TO START IN H2 2021

Hamburg, Germany, 20 April 2021:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.

J.POD® 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's first J.POD® 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021.

With its wholly owned subsidiary, Just – Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense.

In addition to J.POD® technology, Evotec is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents.


Protein degradation partnership extended and expanded

Alliance with BMS since 2018 – already proven to be highly productive



Proteomics approach to targeted protein degradation

- Development of novel therapies for a broad range of diseases
- Opportunity to expand and accelerate with AI/ML



“Evotec Inside” – Fully invested pipeline gaining visibility

Progress of drug candidates in advanced stages

Selected pipeline events within next 18 – 24 months

- Phase III data (China) with JingXin in insomnia
- Phase IIb data with Bayer in RCC (eliapixant) ✓
- Phase II data with Bayer in Overactive bladder (eliapixant)
- Phase II with Bayer in Endometriosis (eliapixant)
- Phase II with Bayer in Neuropathic pain (eliapixant)
- Phase II with Bayer in Gynaecology (B1 antagonist)
- Phase I data in Chikungunya virus
- Phase I initiation with BMS in CNS
- Phase I data with Exscientia in Oncology (A2a)
- Phase I initiation with Kazia in Oncology (EVT801)
- Phase I with Sanofi in HBV
- Multiple co-owned equity companies will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...)

	Molecule	Therapeutic Area/Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Clinical	EVT201	Insomnia (GABA-A)	京新药业					
	BAY-1817080	Chronic cough (P2X3)						
	BAY-1817080	Overactive bladder						
	BAY-1817080	Neuropathic pain						
	BAY-1817080	Endometriosis						
	CT7001	Oncology (CDK7)	Carrick					
	CT7001	Oncology (CDK7)	Carrick					
	EVT401	Immunology & Inflammation (P2X7)	康希诺生物					
	BAYxxx	Women's health						
	BAY2328065	Gynaecology						
	BI 894416	Asthma (not disclosed)	Boehringer Ingelheim					
	BI 860585	Oncology (mTORC1/2)	Boehringer Ingelheim, SynGene					
	TPM203	Pemphigus Vulgaris (not disclosed)	Topas Therapeutics					
	DSP-1181	Obsessive-compulsive disorder (5-HT1A)	Exscientia					
	CNTX 6016	Pain (CB2)	Boehringer Ingelheim					
EVT894	Chikungunya (Antibody)	NIA, SANOFI						
Pre-clinical	BAYxxx	Endometriosis (not disclosed)						
	EVT801	Oncology (VEGFR3)	SANOFI					
	APN411	Oncology – Immunotherapy	SANOFI, APEIRON					
	EXS21546	Oncology (various programmes)	Exscientia					
	GLPGxxxx	Fibrosis (not disclosed)	Galapagos					
	BAYxxxx	Nephrology (not disclosed)						
	QRB001	Metabolic – Diabetes (not disclosed)	QRbeta					
	BMSxxxx	Neurodegeneration (not disclosed)	Bristol Myers Squibb					
	EVT895	HBV	SANOFI					
	EVTxxxx	CNS, Metabolic, Pain ...	>10 further programmes					
Discovery	Multiple programs across nephrology, oncology, immunology among other therapeutic areas							

Positive Phase IIb headline data supports best-in-class potential


P2X₃ antagonist – eliapixant (BAY1817080) **Refractory Chronic Cough (RCC)**

Positive outcome of Phase IIb trial (PAGANINI)

- Statistically significant improvement in 24-hour cough counts per hour over placebo after 12 weeks of treatment²⁾
- Positive outcome in chronic cough regarding efficacy, safety and differentiation³⁾
- Favourable safety and tolerability profile

Cough frequency in Phase IIa¹⁾

Mean relative change in hourly cough frequency assessed over 24-hour periods versus placebo



Vertical lines show 90% credible limits. Duration of treatment was 1 week with each dose of BAY 1817080.

Multiple indications potential



Detailed efficacy and safety data will be presented by Bayer at upcoming scientific congress

1) Sources: <https://conference.thoracic.org/> Poster presented on the ATS 2020 International Conference Virtual Platform


2) Average hourly cough frequency based on 24-hour sound recordings

3) Source: <https://media.bayer.com/baynews/baynews.nsf/id/A3224676255E5482C125872600261CAE?open&ref=irrefndcd>

PRROtect


Lessons from COVID-19

*Building a unique pandemic
Preparedness and Rapid
RespOnse TEChnology
PlaTform*



Welcome back, Kara!

Kara Carter re-joining Evotec to strengthen Evotec's position in Virology




“Chronic Hepatitis B continues to have a tremendous burden on global health. Finding a cure for this disease requires innovative approaches and is critically important to improving the health of millions of patients world wide.”

Kara Carter

Keeping the promise

ESG & Sustainability – Measures taken in H1 2021



Responsible use of resources

- Sourcing of 100% renewable energy since January 2021 at all German sites
- Decision on replacement of heating system in building B95 in Abingdon (estimated savings of CO₂e of ~800t per year as of Q2 2022)

ESG topics part of our DNA


- Group-wide inclusion of ESG topics in personal 2021 targets of all employees
- Definition of responsibilities for delivering expanded set of sustainability KPIs
- Group-wide appreciation & celebration of Diversity weeks in May and pride month in June

Intensified stakeholder dialogue

- Increasing awareness and appreciation of investors and rating agencies
- MSCI ESG rating up from BBB to A as of January 2021
- ISS ESG rating up from C- to C as of May 2021

BRIDGEs bring multiple future investment options












Creating long-term optionality with efficient translation














Growing portfolio with operational synergies

EVOequity overview

At equity investments (share ≥ 20% or significant influence)

										Joint Venture
										
Equity participation	Spin-off	Equity participation	Equity (in-kind)	Spin-off	Equity participation	Equity participation	Spin-off (LAB282)	Equity participation	Equity participation and partnership	Joint Venture with Vifor Pharma
Metabolic disorders	Nanoparticle-based therapeutics	FSHD	Cross therapeutic areas	DNA damage response	Women's health	Cross therapeutic areas	Oncology	Failsafe cloaking for cell therapies	Oncology	Nephrology
<i>Initiated 2016</i>	<i>Initiated 2016</i>	<i>Initiated 2017</i>	<i>Initiated 2019</i>	<i>Initiated 2019</i>	<i>Initiated 2019</i>	<i>Initiated 2020</i>	<i>Initiated 2020</i>	<i>Initiated 2020</i>	<i>Initiated 2020</i>	<i>Initiated 2019</i>

Minority Shareholdings (share < 20%)

										
Equity participation	Equity participation	Equity participation	Equity participation	Equity participation	Equity participation	Equity participation	Equity participation	Venture fund	Equity participation	Equity participation
Innovative pathways in oncology	AI for auto-mated drug design	Targeting metallo-enzymes	Fibrosis partnership	Inflammatory disease	Oncology / Biologics	Oncology	Formulation nanotechnologies	Invests into early-stage life science companies	Neuro-science	Immuno-oncology
<i>Initiated 2016</i>	<i>Initiated 2017</i>	<i>Initiated 2017</i>	<i>Initiated 2017</i>	<i>Initiated 2019</i>	<i>Initiated 2019</i>	<i>Initiated 2019</i>	<i>Initiated 2020</i>	<i>Initiated 2020</i>	<i>Initiated 2020</i>	<i>Initiated 2021</i>

New

New


Agenda

Highlights

Financial performance H1 2021


“Building for growth”

Guidance 2021



Strong year ahead

Guidance 2021



Very good top-line growth expected

- Assumption based on current orders, prospective milestone payments
- Total Group revenues **€ 550-570 m** (€ 565-585 m at constant exchange rates¹⁾⁾)

EBITDA guidance confirmed – despite massive investments

- Expanding scope of strategic investments for promising R&D projects, ramp-up of Just – Evotec Biologics business, expansion of J.POD[®] 1 US capacities in US & J.POD[®] 2 EU
- Adjusted Group EBITDA²⁾ **€ 105-120 m** (€ 115-130 m at constant exchange rates¹⁾⁾)

Accelerated R&D investments for growth

- Further expand long-term & sustainable pipeline of first-in-class projects & platforms
- Unpartnered Group R&D expenses of **€ 50-60 m³⁾**






¹⁾ \$/€ 2020: 1.15; €/GBP 2020: 1.13

²⁾ Before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result

³⁾ Evotec focuses its guidance and upcoming reporting on the “unpartnered R&D” part. ID-related R&D expenses will be fully reimbursed by its partner Sanofi (“partnered R&D”).

Our mid-term aspirations are “...just the beginning”

2020-2025e Key Performance Indicator goals




¹⁾ before significant royalties

²⁾ incl. Equity participations

Upcoming important dates

Financial calendar 2021

Quarterly Statement Q1 2021		11 May 2021
Virtual Annual General Meeting 2021		15 June 2021
Half-year 2021 Interim Report		11 August 2021
Quarterly Statement 9M 2021		11 November 2021
Virtual Capital Markets Day		02 December 2021



#RESEARCHNEVERSTOPS




RIGHT NOW, WE HAVE TO WAIT.

We will switch to virtual

CAPITAL MARKETS DAY ON 02 DECEMBER 2021

QUESTIONS
AND ANSWERS



Your contact:

Dr Werner Lanthaler
Chief Executive Officer

+49.(0).40.560 81-242

+49.(0).40.560 81-333 Fax


werner.lanthaler@evotec.com

Appendix

Plenty of headroom despite significant capex & equity invested

Liquidity bridge H1 2021


in € m



Further improvement of accounts receivables management

Days Sales Outstanding comfortably within target range

DSO quarterly and LTM DSO average in days



- Trade accounts receivables including receivables from associated companies decreased to € 79.8m (Dec 2020: € 87.9m)
- Days Sales Outstanding (DSO) of 53 comfortably within target range of 50-60 days
- Effect from extension of alliance with BMS in protein degradation at the end of Q1 mitigated in Q2 as planned
- Reduction of DSO by 27 days versus Q2 2020

Our purpose is to go VERY long as ONE – *#researchneverstops*

Sustainable thinking is holistic and ensures long-term success

